Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Brown snake antivenom is a purified equine-derived immunoglobulin (typically F(ab')2 fragments) used to treat envenomation by snakes of the genus *Pseudonaja* (brown snakes). The venom of these snakes is highly potent, primarily causing venom-induced consumptive coagulopathy (VICC) through the action of prothrombin activators, as well as neurotoxicity and occasionally nephrotoxicity. The antivenom works by binding to and neutralizing these circulating toxins. While specifically designed for *Pseudonaja* species, it has demonstrated clinical utility in treating envenomation by other species, such as the Pygmy Mulga snake (*Pseudechis pailsei*), due to cross-reactivity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on brown snake antivenom.